Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
Source :
Auteur : Ling LiWei ZhangYu Hu; et al
ANALYSE
Commentateur
Dr REY David
Objectif
Evaluer l’efficacité et la tolérance de transfusion de plasma de personnes convalescentes (guérison depuis au moins 2 semaines, PCR négativée 2 fois, 18-55 ans, vérification sérologie COVID).
Points forts
Etude randomisée comparative.
Points faibles
Fin d’étude prématurée (fin d’épidémie), donc effectif inférieur aux 200 patients prévus. Autres traitements possibles (antiviraux, corticoïdes), sans “contrôle” entre les 2 groupes.
Conclusion
Globalement pas de bénéfice clinique de la transfusion de plasma; petit bénéfice pour les formes sévères sans engagement du pronostic vital. Négativation des PCR plus rapides après transfusion de plasma.
Vous pouvez télécharger l’analyse ICI.
IMPORTANT
Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed.
OBJECTIVE
To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19.
CONCLUSION AND RELEVANCE
Among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days. Interpretation is limited by early termination of the trial, which may have been underpowered to detect a clinically important difference.